As of end-June, Bioepis was 91.2 percent owned by Samsung BioLogics, which separately on Tuesday announced plans for an initial public offering that could raise up to 2.25 trillion won ($2 billion). BioLogics is controlled by Samsung Group's de facto holding company Samsung C&T Corp and Samsung Electronics Co Ltd. US biopharmaceuticals maker Biogen Inc is a minority shareholder in Bioepis with an 8.8 percent stake as of end-June. Bioepis, which seeks to be first or second to market with its products, received European regulatory approval earlier this year to sell copies of Amgen Inc's Enbrel and Johnson & Johnson's Remicade – two blockbuster rheumatoid arthritis drugs. It is also seeking European approval for its biosimilar of arthritis treatment Humira, the world's top-selling drug. ($1 = 0.9741 Swiss francs) ($1 = 1,103.3300 won)